Alzheimer s Research & TherapyNeurosciencePeer-reviewed journal article
Metabolic Alteration in Oxylipins and Endocannabinoids Point to an Important Role for Soluble Epoxide Hydrolase and Inflammation in Alzheimer's Disease - Finding from Alzheimer's Disease Neuroimaging Initiative.
Kamil BorkowskiiD, Chunyuan YiniD, Alida Kindt, Nuanyi LiangiD, Elizabeth C. M. de LangeiD, Colette BlachiD, John W. I. NewmaniD, Rima F Kaddurah-DaoukiD, Thomas HankemeieriD, the Frontotemporal Lobar Degeneration Neuroimaging Initiative
Abstract
Mounting evidence implicates inflammation as a key factor in Alzheimers disease (AD) development. We previously identified pro-inflammatory soluble epoxide hydrolase (sEH) metabolites to be elevated in plasma and CSF of AD patients and to be associated with lower cognition in non-AD subjects. Soluble epoxide hydrolase is a key enzyme converting anti-inflammatory epoxy fatty acids to pro-inflammatory diols, reported to be elevated in multiple cardiometabolic disorders. Here we analyzed over 700 fasting plasma samples from the baseline of Alzheimers Disease Neuroimaging Initiative (ADNI) 2/GO study. We applied targeted mass spectrometry method to provide absolute quantifications of over 150 metabolites from oxylipin and endocannabinoids pathway, interrogating the role for inflammation/immune dysregulation and the key enzyme soluble epoxide hydrolase in AD. We provide further insights into the regulation of this pathway in different disease stages, APOE genotypes and between sexes. Additionally, we investigated in mild cognitive impaired (MCI) patients, metabolic signatures that inform about resilience to progression and conversion to AD. Key findings include I) confirmed disruption in this key central pathway of inflammation and pointed to dysregulation of sEH in AD with sex and disease stage differences; II) identified markers of disease progression and cognitive resilience using sex and ApoE genotype stratified analysis highlighting an important role for bile acids, lipid peroxidation and stress response hormone cortisol. In conclusion, we provide molecular insights into a central pathway of inflammation and links to cognitive dysfunction, suggesting novel therapeutic approaches that are based on targeting inflammation tailored for subgroups of individuals based on their sex, APOE genotype and their metabolic profile.
- organism: human
- assay: metabolomics
- research focus: differential expression
- approach: statistical model
- Citations
- 5
- FWCI
- 13.71
- Field percentile
- top 2%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Pharmacological inhibition of soluble epoxide hydrolase as a new therapy for Alzheimer’s Disease
C. Grinyan-Ferre, S. Codony, … C. Galdeano·bioRxiv·Apr 10, 2019
- Epoxy fatty acid dysregulation and neuroinflammation in Alzheimer's disease is resolved by a soluble epoxide hydrolase inhibitor
Anamitra Ghosh, Michele M. Comerota, … Hui Zheng·bioRxiv·Jun 30, 2020
- Soluble epoxide hydrolase upregulation in Alzheimer's disease promotes blood-brain barrier dysfunction
Murphy DeMeglio, Eloah S. De Biasi, … Jasmin K. Hefendehl·bioRxiv·Dec 11, 2025
- Inhibition of Soluble Epoxide Hydrolase Rescues Cognitive Deficits by Preserving Neurovascular Integrity and Attenuating Glial- and Neuropathology in Diabetic-Related Dementia
Xing Fang, Jane J. Border, … Richard J. Roman·bioRxiv·Jun 4, 2026
- The Alzheimer’s Disease Metabolome: Effects of Sex and APOE ε4 genotype
Matthias Arnold, Kwangsik T. Nho, … Gabi Kastenmüller·Nature CommunicationsPeer-reviewed·Mar 2, 2020
- Inflammation in Alzheimer's disease: do sex and APOE matter?
Paula Duarte‐Guterman, on behalf of the Alzheimer’s Disease Neuroimaging Initiative, … Liisa A.M. Galea·Journal of Alzheimer s DiseasePeer-reviewed·Sep 29, 2020